ES-62 protects against collagen-induced arthritis by resetting interleukin-22 toward resolution of inflammation in the joints

Arthritis and Rheumatology

Volumn 66, Issue 6, 2014, Pages 1492-1503

  Pineda, Miguel A ^a   Rodgers, David T ^a   Al Riyami, Lamyaa ^b   Harnett, William ^b   Harnett, Margaret M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; ES 62; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 17; INTERLEUKIN 22; NEUTRALIZING ANTIBODY; RECOMBINANT CYTOKINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DESENSITIZATION; EX VIVO STUDY; FIBROBLAST; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYNOVIAL FIBROBLAST; SYNOVIOCYTE;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, EXPERIMENTAL; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HELMINTH PROTEINS; INFLAMMATION; INTERLEUKIN-17; INTERLEUKINS; JOINTS; MALE; MICE; MICE, INBRED DBA;

EID: 84901642275     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38392     Document Type: Article

References (47)

1. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005; 167: 141-9.
2. Kim KW, Cho ML, Park MK, Yoon CH, Park SH, Lee SH, et al. Increased interleukin-17 production via a phosphoinositide 3kinase/Akt and nuclear factor κB-dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther 2005; 7: R139-48.
3. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203: 2673-82.
4. Shen H, Goodall JC, Hill Gaston JS,. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60: 1647-56.
5. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010; 62: 2876-85.
6. Nakae S, Nambu A, Sudo K, Iwakura Y,. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171: 6173-7.
7. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004; 50: 650-9.
8. Harnett W, Harnett MM,. Helminth-derived immunomodulators: can understanding the worm produce the pill? Nat Rev Immunol 2010; 10: 278-84.
9. McInnes IB, Leung BP, Harnett M, Gracie JA, Liew FY, Harnett W,. A novel therapeutic approach targeting articular inflammation using the filarial nematode-derived phosphorylcholine-containing glycoprotein ES-62. J Immunol 2003; 171: 2127-33.
10. Harnett MM, Kean DE, Boitelle A, McGuiness S, Thalhamer T, Steiger CN, et al. The phosphorycholine moiety of the filarial nematode immunomodulator ES-62 is responsible for its anti-inflammatory action in arthritis. Ann Rheum Dis 2008; 67: 518-23.
11. Pineda MA, McGrath MA, Smith PC, Al-Riyami L, Rzepecka J, Gracie JA, et al. The parasitic helminth product ES-62 suppresses pathogenesis in collagen-induced arthritis by targeting the interleukin-17-producing cellular network at multiple sites. Arthritis Rheum 2012; 64: 3168-78.
12. Stockinger B, Veldhoen M, Hirota K,. Modulation of Th17 development and function by activation of the aryl hydrocarbon receptor-the role of endogenous ligands. Eur J Immunol 2009; 39: 652-4.
13. H17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-51.
14. H17-cell-mediated autoimmunity to environmental toxins. Nature 2008; 453: 106-9.
15. H2 cells. Nat Immunol 2009; 10: 864-71.
16. Eyerich S, Eyerich K, Cavani A, Schmidt-Weber C,. IL-17 and IL-22: siblings, not twins. Trends Immunol 2010; 31: 354-61.
17. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R,. IL-22 increases the innate immunity of tissues. Immunity 2004; 21: 241-54.
18. Sonnenberg GF, Fouser LA, Artis D,. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011; 12: 383-90.
19. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA,. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27: 647-59.
20. Monteleone I, Rizzo A, Sarra M, Sica G, Sileri P, Biancone L, et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 2011; 141: 237-48, 48 e1.
21. Kreymborg K, Etzensperger R, Dumoutier L, Haak S, Rebollo A, Buch T, et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007; 179: 8098-104.
22. Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC, et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum 2009; 60: 390-5.
23. Corneth O, Mus AM, Asmawidjaja P, Ouyang W, Kil L, Hendriks R, et al. Impaired B cell immunity in IL-22 knock-out mice in collagen-induced arthritis. Ann Rheum Dis 2011; 70: A58-9.
24. 3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum 2010; 62: 132-42.
25. Zhang L, Li YG, Li YH, Qi L, Liu XG, Yuan CZ, et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One 2012; 7: e31000.
26. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005; 52: 1037-46.
27. Kim KW, Kim HR, Park JY, Park JS, Oh HJ, Woo YJ, et al. Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum 2012; 64: 1015-23.
28. Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-Joannopoulos K, et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol 2012; 188: 462-9.
29. Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikolaidou-Katsaridou N, Zhao Z, et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med 2012; 209: 925-33.
30. Da Rocha LF Jr, Duarte AL, Dantas AT, Mariz HA, Pitta Ida R, Galdino SL, et al. Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. J Rheumatol 2012; 39: 1320-5.
31. Mor A, Abramson SB, Pillinger MH,. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 2005; 115: 118-28.
32. Carrion M, Juarranz Y, Martinez C, Gonzalez-Alvaro I, Pablos JL, Gutierrez-Canas I, et al. IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford) 2013; 52: 2177-86.
33. Bottini N, Firestein GS,. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol 2013; 9: 24-33.
34. Juarez M, Filer A, Buckley CD,. Fibroblasts as therapeutic targets in rheumatoid arthritis and cancer. Swiss Med Wkly 2012; 142: w13529.
35. Lefevre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 2009; 15: 1414-20.
36. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008; 14: 275-81.
37. Dambacher J, Beigel F, Zitzmann K, Heeg MH, Goke B, Diepolder HM, et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine 2008; 41: 209-16.
38. Kondrashova A, Seiskari T, Ilonen J, Knip M, Hyoty H,. The 'hygiene hypothesis' and the sharp gradient in the incidence of autoimmune and allergic diseases between Russian Karelia and Finland. APMIS 2013; 121: 478-93.
39. Pennino D, Bhavsar PK, Effner R, Avitabile S, Venn P, Quaranta M, et al. IL-22 suppresses IFN-γ-mediated lung inflammation in asthmatic patients. J Allergy Clin Immunol 2013; 131: 562-70.
40. Simonian PL, Wehrmann F, Roark CL, Born WK, O'Brien RL, Fontenot AP,. γδ T cells protect against lung fibrosis via IL-22. J Exp Med 2010; 207: 2239-53.
41. Besnard AG, Sabat R, Dumoutier L, Renauld JC, Willart M, Lambrecht B, et al. Dual role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A. Am J Respir Crit Care Med 2011; 183: 1153-63.
42. Hirose K, Takahashi K, Nakajima H,. Roles of IL-22 in allergic airway inflammation. J Allergy (Cairo) 2013; 2013: 260518.
43. Van Hamburg JP, Corneth OB, Paulissen SM, Davelaar N, Asmawidjaja PS, Mus AM, et al. IL-17/Th17 mediated synovial inflammation is IL-22 independent. Ann Rheum Dis 2013; 72: 1700-7.
44. Sarkar S, Zhou X, Justa S, Bommireddy SR,. Interleukin-22 reduces the severity of collagen-induced arthritis in association with increased levels of interleukin-10. Arthritis Rheum 2013; 65: 960-71.
45. Marijnissen RJ, Koenders MI, Smeets RL, Stappers MH, Nickerson-Nutter C, Joosten LA, et al. Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation. Arthritis Rheum 2011; 63: 2939-48.
46. Broadhurst MJ, Leung JM, Kashyap V, McCune JM, Mahadevan U, McKerrow JH, et al. IL-22+ CD4+ T cells are associated with therapeutic Trichuris trichiura infection in an ulcerative colitis patient. Sci Transl Med 2010; 2: 60ra88.
47. Al-Riyami L, Pineda MA, Rzepecka J, Huggan JK, Khalaf AI, Suckling CJ, et al. Designing anti-inflammatory drugs from parasitic worms: a synthetic small molecule analogue of the Acanthocheilonema viteae product ES-62 prevents development of collagen-induced arthritis. J Med Chem 2013; 56: 9982-10002.